Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.

IRF4 addiction in multiple myeloma. Nature (2008) 6.27

Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49

Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A (2011) 2.12

Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia (2013) 1.76

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50

The forkhead transcription factor FOXP1 represses human plasma cell differentiation. Blood (2015) 1.47

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics (2008) 1.25

Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One (2009) 1.18

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2008) 1.16

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood (2010) 1.11

Pathophysiology of Waldenström's macroglobulinemia. Haematologica (2010) 1.07

Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics (2011) 1.05

Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol (2008) 0.98

Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol (2009) 0.96

The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol (2012) 0.95

Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget (2015) 0.95

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica (2014) 0.89

Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol (2011) 0.87

Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomarkers Prev (2013) 0.84

The eleven-nineteen lysine-rich leukemia gene (ELL2) influences the histone H3 protein modifications accompanying the shift to secretory immunoglobulin heavy chain mRNA production. J Biol Chem (2011) 0.84

ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA. PLoS One (2012) 0.83

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood (2016) 0.82

Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology (2015) 0.82

High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma (2009) 0.81

Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells. Mol Cancer Ther (2013) 0.81

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget (2013) 0.81

MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer J (2011) 0.81

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Haematologica (2012) 0.79

Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol (2013) 0.79

Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica (2012) 0.78

Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells. Oncotarget (2015) 0.78

Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells. Immunol Cell Biol (2014) 0.78

Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia. PLoS One (2013) 0.78

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol (2011) 0.78

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia (2015) 0.78

MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia. Biomed Res Int (2014) 0.78

Aberrant Wnt Signaling in Leukemia. Cancers (Basel) (2016) 0.77

Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. Blood Cancer J (2012) 0.77

Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia. Am J Cancer Res (2015) 0.76

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. Blood Cancer J (2014) 0.76

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol (2017) 0.75

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. Blood Cancer J (2016) 0.75

Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet (2013) 0.75

IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events. Leukemia (2014) 0.75

Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival. PLoS One (2015) 0.75

Network Biomarkers Constructed from Gene Expression and Protein-Protein Interaction Data for Accurate Prediction of Leukemia. J Cancer (2017) 0.75

The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance. Oncotarget (2016) 0.75

Genetic factors and pathogenesis of Waldenström's macroglobulinemia. Curr Oncol Rep (2013) 0.75

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. Oncogene (2015) 0.75

EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies. Blood (2016) 0.75

Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget (2016) 0.75

Exploring the nature of prediagnostic blood transcriptome markers of chronic lymphocytic leukemia by assessing their overlap with the transcriptome at the clinical stage. BMC Genomics (2017) 0.75

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma. Nucl Recept Signal (2015) 0.75

Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clin Adv Hematol Oncol (2009) 0.75

Transgenic mouse model of IgM(+) lymphoproliferative disease mimicking Waldenström macroglobulinemia. Blood Cancer J (2016) 0.75

High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Oncotarget (2016) 0.75

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia. Oncotarget (2016) 0.75

The transcriptional profiling of human in vivo-generated plasma cells identifies selective imbalances in monoclonal gammopathies. PLoS One (2017) 0.75

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia (1999) 4.09

Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 4.06

Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature (2001) 4.00

Hepatitis C virus antibodies among risk groups in Spain. Lancet (1989) 3.66

Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) (1996) 3.23

Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med (1990) 2.50

Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) (2008) 2.09

Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens. Am J Epidemiol (1990) 1.95

Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 1.86

High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol (1999) 1.84

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 1.83

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia (2006) 1.73

Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia (2010) 1.66

Recent improvement in long-term survival after a COPD hospitalisation. Thorax (2010) 1.65

Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood (1991) 1.64

Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet (1996) 1.61

Two-stage treatment with preoperative endoscopic retrograde cholangiopancreatography (ERCP) compared with single-stage treatment with intraoperative ERCP for patients with symptomatic cholelithiasis with possible choledocholithiasis. Endoscopy (2006) 1.61

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia (1999) 1.55

Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia (2003) 1.52

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48

Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. Am J Hematol (1993) 1.48

Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion (2002) 1.48

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica (1998) 1.48

1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res (1983) 1.48

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia (2012) 1.45

Minimal residual disease in leukaemia patients. Lancet Oncol (2001) 1.43

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia (2012) 1.41

Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant (1999) 1.41

Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.41

[Campylobacter jejuni infection in children of a rural community]. Bol Med Hosp Infant Mex (1991) 1.40

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol (2000) 1.40

[Familial transmission of hepatitis C virus]. Rev Esp Enferm Dig (1996) 1.40

[Cesarean section in a patient with a congenital deficit of antithrombin III: apropos of a case]. Rev Esp Anestesiol Reanim (1996) 1.40

[Transesophageal echocardiography in mitral prosthesis dysfunction: usefulness and limitations in the evaluation of mitral insufficiency]. Rev Esp Cardiol (1993) 1.40

A real-coded genetic algorithm for training recurrent neural networks. Neural Netw (2001) 1.40

BN 52021 (a platelet activating factor-receptor antagonist) decreases alveolar macrophage-mediated lung injury in experimental extrinsic allergic alveolitis. Mediators Inflamm (1998) 1.39

Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1,2 dimethyl-hydrazine (DMH). Rev Esp Enferm Dig (2005) 1.39

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood (1989) 1.31

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia (2013) 1.30

Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia (2005) 1.29

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia (2009) 1.29

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29

Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut (2006) 1.28

Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia (2005) 1.27

Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J (1999) 1.26

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia (2005) 1.26

Publication bias in health economic studies. Pharmacoeconomics (1997) 1.26

BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia (2000) 1.24

Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol (2000) 1.23

Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia (2001) 1.22

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia (2006) 1.20

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant (1997) 1.19

The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia (2008) 1.17

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood (1998) 1.17

Influence of trial registration on reporting quality of randomized trials: study from highest ranked journals. J Clin Epidemiol (2010) 1.15

Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol (1999) 1.15

Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant (2003) 1.14

Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain. Haematologica (2001) 1.12

Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol (2001) 1.11

MRI shows abnormal white matter maturation in classical holoprosencephaly. Neurology (2002) 1.11

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia (2002) 1.11

Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol (1984) 1.10

Strategic intervention: a mental health program for the Hispanic community. J Community Psychol (1979) 1.09

High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol (2003) 1.08

Bacteriophage treatment reduces Salmonella colonization of infected chickens. Avian Dis (2008) 1.08

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07

Distribution patterns of phosphorylated Thr 3 and Thr 32 of histone H3 in plant mitosis and meiosis. Cytogenet Genome Res (2008) 1.06

Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia (2005) 1.05

Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells. Clin Exp Immunol (1999) 1.05

Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol (2001) 1.04

Cell surface markers in multiple myeloma. Mayo Clin Proc (1994) 1.04

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol (1998) 1.04

Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. Bone Marrow Transplant (2004) 1.04

Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol (1991) 1.03

Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods. Cytometry (2001) 1.02

Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des (2001) 1.02

BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia (2001) 1.02

Receptor aggregation induced by antilutropin receptor antibody and biological response in rat testis Leydig cells. Proc Natl Acad Sci U S A (1983) 1.02

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol (1996) 1.02

Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol (2003) 1.01